Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease.
Celińska-Löwenhoff
Magdalena
M
Löwenhoff
Tomasz
T
Undas
Anetta
A
Gluszko
Piotr
P
D015519:Bone Density / Q000187:drug effects; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000378:metabolism*; D004311:Double-Blind Method; D011345:Fenofibrate / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood*; D053245:RANK Ligand / Q000097:blood*; D019821:Simvastatin / Q000494:pharmacology; D012995:Solubility
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D053244:Osteoprotegerin; D053245:RANK Ligand; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D019821:Simvastatin; D011345:Fenofibrate